Estrella Immunopharma Files 8-K: Other Event Reported
Ticker: ESLAW · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1844417
| Field | Detail |
|---|---|
| Company | Estrella Immunopharma, INC. (ESLAW) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $35,000,000, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, company-update
Related Tickers: ESLA
TL;DR
ESLA filed an 8-K for an 'Other Event' on 12/16/24 - details TBD.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on December 16, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar amounts, or definitive dates beyond the filing date itself. The company was formerly known as TradeUP Acquisition Corp. and changed its name on February 4, 2021.
Why It Matters
This 8-K filing indicates a material event has occurred for Estrella Immunopharma, Inc., requiring disclosure to investors, though the specifics are not yet detailed.
Risk Assessment
Risk Level: medium — The filing is an 8-K for an 'Other Event' without immediate details, creating uncertainty for investors.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- TradeUP Acquisition Corp. (company) — Former company name
- February 4, 2021 (date) — Date of name change
- December 16, 2024 (date) — Date of report
FAQ
What specific event is being reported in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the event itself within the provided text.
When was this 8-K report filed?
The report was filed on December 16, 2024.
What was Estrella Immunopharma, Inc. formerly known as?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp.
When did the company change its name from TradeUP Acquisition Corp. to Estrella Immunopharma, Inc.?
The name change occurred on February 4, 2021.
What is the principal business address of Estrella Immunopharma, Inc.?
The principal business address is 5858 Horton Street, Suite 370, Emeryville, California 94608.
Filing Stats: 626 words · 3 min read · ~2 pages · Grade level 13.2 · Accepted 2024-12-16 16:00:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
- $35,000,000 — ket value of listed securities has been $35,000,000 or greater. Accordingly, the Company ha
- $1.00 — e Company's common stock has been below $1.00 per share for 30 consecutive business d
Filing Documents
- ea0224902-8k_estella.htm (8-K) — 31KB
- 0001213900-24-109285.txt ( ) — 246KB
- esla-20241216.xsd (EX-101.SCH) — 4KB
- esla-20241216_def.xml (EX-101.DEF) — 26KB
- esla-20241216_lab.xml (EX-101.LAB) — 36KB
- esla-20241216_pre.xml (EX-101.PRE) — 25KB
- ea0224902-8k_estella_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, on November 19, 2024, Estrella Immunopharma, Inc. (the "Company") received a notification letter (the "Stockholders' Equity Requirement Notice") from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). On December 11, 2024, the Company received a notification letter from Nasdaq stating that for the last 10 consecutive business days, from November 25, 2024 to December 10, 2024, the Company's market value of listed securities has been $35,000,000 or greater. Accordingly, the Company has regained compliance with the Stockholders' Equity Requirement, and this matter is now closed. Additionally, as previously disclosed, on November 19, 2024, the Company received a notification letter (the "Minimum Bid Price Deficiency Notice") from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5550(a)(2), as the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days (the "Minimum Bid Price Requirement"). On December 11, 2024, the Company received a notification letter from Nasdaq stating that for the last 10 consecutive business days, from November 25, 2024 to December 10, 2024, the closing bid price of the Company's common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and this matter is now closed. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Peter Xu Name: Peter Xu Title: Chief Financial Officer Date: December 16, 2024 2